1-3 of 3
Michael Gent, DSc
Close
Sort by
Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP
Journal: Blood
Blood (2009) 114 (22): 2099.
https://doi.org/10.1182/blood.V114.22.2099.2099
Published: 2009
Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Bengt Eriksson, MD, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, MD, Martin Homering, Torsten Westermeier, PhD, Michael Gent, DSc
Journal: Blood
Blood (2008) 112 (11): 36.
https://doi.org/10.1182/blood.V112.11.36.36
Published: 2008
Journal Articles

Fondaparinux Combined with Intermittent Pneumatic Compression (IPC) Versus IPC Alone in the Prevention of Venous Thromboembolism after Major Abdominal Surgery: The Randomized APOLLO Study.

Alexander G.G. Turpie, FRCP, Kenneth A. Bauer, MD, Joseph A. Caprini, MD, Philip P. Comp, MD, Michael Gent, DSc, James E. Muntz, MD
Journal: Blood
Blood (2005) 106 (11): 279.
https://doi.org/10.1182/blood.V106.11.279.279
Published: 2005